sTWEAK is a leukoaraiosis biomarker associated with neurovascular angiopathy
Objective Leukoaraiosis (LA) refers to white matter lesions of undetermined etiology associated with the appearance and worsening of vascular pathologies. The aim is to confirm an increased frequency and intensity of LA in symptomatic patients with neurovascular pathology compared with asymptomatic...
Saved in:
Published in | Annals of clinical and translational neurology Vol. 9; no. 2; pp. 171 - 180 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.02.2022
John Wiley & Sons, Inc Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Objective
Leukoaraiosis (LA) refers to white matter lesions of undetermined etiology associated with the appearance and worsening of vascular pathologies. The aim is to confirm an increased frequency and intensity of LA in symptomatic patients with neurovascular pathology compared with asymptomatic subjects, and its association with circulating serum levels of soluble tumor necrosis factor‐like weak inducer of apoptosis (sTWEAK).
Methods
An observational study was conducted in which two groups of patients were compared. Group I (N = 242) comprised of asymptomatic subjects with arterial hypertension and/or diabetes or with a history of transient ischemic attacks, and Group II (N = 382) comprised patients with lacunar stroke or deep hemispheric intracerebral hemorrhage (ICH) of hypertensive origin. Serum levels of sTWEAK were analyzed and correlated with prevalence and intensity of LA according to the Fazekas scale.
Results
The prevalence of LA was higher in symptomatic (85.1%) versus asymptomatic patients (62.0%). Logistic regression model showed a significant relation of LA with neurovascular pathologies (OR: 2.69, IC 95%: 1.10–6.59, p = 0.003). When stratified according to the Fazekas scale, LA of grade II (OR: 3.53, IC 95%: 1.10–6.59, p = 0.003) and specially grade III (OR: 4.66, 95% CI: 1.09–19.84, p = 0.037) showed correlation with neurovascular pathologies. Increased sTWEAK levels were found in the symptomatic group in all LA grades (p < 0.0001), and associated with 5.06 times more risk of presenting clinical symptoms (OR: 5.06, 95% CI: 2.66–9.75, p < 0.0001).
Interpretation
LA showed a higher prevalence in patients with symptomatic lacunar stroke or deep hemispheric ICH. There is an association between sTWEAK levels and LA degree. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 Funding Information This study was partially supported by grants from the Spanish Ministry of Economy and Competitiveness (SAF2017‐84267‐R; RTI2018‐102165‐B‐I00), Xunta de Galicia (Consellería de Economía e Industria (IN607A2018/3; IN607D2020/09), Instituto de Salud Carlos III (PI17/01103), and Spanish Research Network on Cerebrovascular Diseases RETICS‐INVICTUS PLUS (RD16/0019). Furthermore, this study was also supported by grants from the INTERREG Atlantic Area (EAPA_791/2018NEUROATLANTIC project), INTERREG V A España Portugal (POCTEP) 0624_2IQBIONEURO_6_E, and the European Regional Development Fund (ERDF). Furthermore, T. Sobrino (CPII17/00027) and F. Campos (CPII19/00020) are recipients of research contracts from the Miguel Servet Program. Andrés Da Silva‐Candal (CD20/00054) recipient of Sara Borrell grant funded by Instituto de Salud Carlos III and co‐funded by European Union, ESF, “Investing in your future.” The sponsors did not participate in the study design, collection, analysis, or interpretation of the data, in writing the report, or in the decision to submit the paper for publication. |
ISSN: | 2328-9503 2328-9503 |
DOI: | 10.1002/acn3.51502 |